Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer.
International journal of clinical oncology / Japan Society of Clinical Oncology 2011 Jun .
Narita S, Tsuchiya N, Yuasa T, Maita S, Obara T, Numakura K, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Habuchi T
- Page last reviewed:Jul 30, 2019
- Page last updated:Sep 18, 2019
- Content source: